Individual heterogeneity screened umbilical cord-derived mesenchymal stromal cells with high Treg promotion demonstrate improved recovery of mouse liver fibrosis

被引:20
|
作者
Xie, Yuanyuan [1 ]
Liu, Shuo [1 ]
Wang, Liudi [1 ]
Yang, Hui [1 ]
Tai, Chenxu [1 ]
Ling, Li [2 ,3 ]
Chen, Libo [2 ,3 ]
Liu, Shanshan [4 ]
Wang, Bin [1 ]
机构
[1] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Clin Stem Cell Ctr, 321 Zhongshan Rd, Nanjing 210000, Peoples R China
[2] Hua Zhong Univ Sci & Technol, Union Shenzhen Hosp, Univ Hlth Sci Ctr, Dept Endocrinol, Shenzhen 518052, Guangdong, Peoples R China
[3] 6th Affiliated Hosp Shenzhen, Shenzhen 518052, Guangdong, Peoples R China
[4] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Rheumatol & Immunol, Med Sch, Nanjing 210000, Peoples R China
基金
中国国家自然科学基金;
关键词
Cell therapy; Umbilical cord mesenchymal stromal cells; Heterogeneity; Differentiation; Immunomodulation; Liver fibrosis; STEM-CELLS; BONE; DIFFERENTIATION; THERAPY; PROLIFERATION; IMMUNOMODULATION; TRANSPLANTATION; OSTEOGENESIS; MECHANISMS; DISEASES;
D O I
10.1186/s13287-021-02430-6
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background To investigate the heterogeneities of human umbilical cord mesenchymal stromal cells (HUCMSCs) derived from different donors and their therapeutic variations when applied to mouse liver fibrosis model. Methods The characteristics of HUCMSCs derived from multiple donors were comprehensively analyzed including expressions of surface markers, viability, growth curve, karyotype analysis, tumorigenicity, differentiation potentials, and immune regulation capability. Then, the HUCMSCs with distinct immunomodulatory effects were applied to treat mouse liver fibrosis and their therapeutic effects were observed. Results The HUCMSCs derived from multiple donors kept a high consistency in surface marker expressions, viability, growth curve, and tumorigenicity in nude mice but had robust heterogeneities in differentiation potentials and immune regulations. In addition, three HUCMSC lines applied to mice liver fibrosis model had different therapeutic outcomes, in line with individual immune regulation capability. Conclusion The HUCMSCs derived from different donors have individual heterogeneity, which potentially lead to distinct therapeutic outcomes in mouse liver fibrosis, indicating we could make use of the donor-variation of MSCs to screen out guaranteed general indicators of MSCs for specific diseases in further stromal cell therapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Individual heterogeneity screened umbilical cord-derived mesenchymal stromal cells with high Treg promotion demonstrate improved recovery of mouse liver fibrosis
    Yuanyuan Xie
    Shuo Liu
    Liudi Wang
    Hui Yang
    Chenxu Tai
    Li Ling
    Libo Chen
    Shanshan Liu
    Bin Wang
    Stem Cell Research & Therapy, 12
  • [2] Banking Human Umbilical Cord-Derived Mesenchymal Stromal Cells for Clinical Use
    Gong, Wei
    Han, Zhibo
    Zhao, Hui
    Wang, Youwei
    Wang, Jiming
    Zhong, Jian
    Wang, Bin
    Wang, Shanshan
    Wang, Yongjuan
    Sun, Lingyun
    Han, Zhongchao
    CELL TRANSPLANTATION, 2012, 21 (01) : 207 - 216
  • [3] Umbilical cord-derived mesenchymal stem cells alleviate liver fibrosis in rats
    Chai, Ning-Li
    Zhang, Xiao-Bin
    Chen, Si-Wen
    Fan, Ke-Xing
    Linghu, En-Qiang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (26) : 6036 - 6048
  • [4] Aging of bone marrow- and umbilical cord-derived mesenchymal stromal cells during expansion
    De Witte, Samantha F. H.
    Lambert, Eleonora E.
    Merino, Ana
    Strini, Tanja
    Douben, Hannie J. C. W.
    O'Flynn, Lisa
    Elliman, Steve J.
    De Klein, Annelies J. E. M. M.
    Newsome, Philip N.
    Barn, Carla C.
    Hoogduijn, Martin J.
    CYTOTHERAPY, 2017, 19 (07) : 798 - 807
  • [5] Human umbilical cord-derived mesenchymal stem cells attenuate hepatic stellate cells activation and liver fibrosis
    Shi, Xiaoyu
    Zhang, Kun
    Qi, Qi
    Zhou, Wangyi
    Yu, Fengshi
    Zhang, Yu
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [6] Chondrogenic Potential of Umbilical Cord-Derived Mesenchymal Stromal Cells: Insights and Innovations
    Jeyaraman, Naveen
    Jeyaraman, Madhan
    Muthu, Sathish
    Balaji, Sangeetha
    Ramasubramanian, Swaminathan
    Patro, Bishnu Prasad
    INDIAN JOURNAL OF ORTHOPAEDICS, 2024, 58 (10) : 1349 - 1361
  • [7] Umbilical cord-derived mesenchymal stem cells alleviate liver fibrosis in rats
    Ning-Li Chai
    Xiao-Bin Zhang
    Si-Wen Chen
    Ke-Xing Fan
    En-Qiang Linghu
    World Journal of Gastroenterology, 2016, 22 (26) : 6036 - 6048
  • [8] Umbilical cord-derived mesenchymal stromal cells: Promising therapy for heart failure
    Li, Ya-Lun
    Chen, En-Guo
    Ren, Bing-Bing
    WORLD JOURNAL OF CARDIOLOGY, 2025, 17 (01):
  • [9] Role of VEGF-A in angiogenesis promoted by umbilical cord-derived mesenchymal stromal/stem cells: in vitro study
    Arutyunyan, Irina
    Fatkhudinov, Timur
    Kananykhina, Evgeniya
    Usman, Natalia
    Elchaninov, Andrey
    Makarov, Andrey
    Bolshakova, Galina
    Goldshtein, Dmitry
    Sukhikh, Gennady
    STEM CELL RESEARCH & THERAPY, 2016, 7
  • [10] Osteogenic potential of human umbilical cord-derived mesenchymal stromal cells cultured with umbilical cord blood-derived autoserum
    Baba, Kyoko
    Yamazaki, Yasuharu
    Ikemoto, Shigehiro
    Aoyagi, Kazuya
    Takeda, Akira
    Uchinuma, Eiju
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2012, 40 (08) : 768 - 772